All In Biotech

Free tool

FAERS Monitor: Rezvoglar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761215 or its brand name (Rezvoglar, Insulin Glargine-Aglr). Reports on generic versions are filed under their own applications.

Reports

77

Serious

13

17% of reports

Hospitalization

8

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased16
  • accidental underdose13
  • incorrect dose administered11
  • product dose omission issue10
  • drug ineffective7
  • injection site haemorrhage6
  • hypoacusis4
  • visual impairment4
  • condition aggravated3
  • death3
  • dyspnoea3
  • inappropriate schedule of product administration3
  • incorrect product administration duration3
  • injection site bruising3
  • injection site pain3

Reports by year received

View as table
YearReports
20211
20233
202411
202532
202630

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,082 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
accidental underdoseSignal13246.9150.42,942
incorrect product administration durationSignal337.812.574
hypoacusisSignal425.49.871
blood glucose increasedSignal1623.215.0321
injection site haemorrhageSignal620.59.593
incorrect dose administeredSignal1113.27.6113
injection site bruisingSignal310.33.417
product dose omission issueSignal109.35.267
visual impairmentSignal48.83.421
inappropriate schedule of product administrationSignal34.51.55
condition aggravated32.70.92
injection site pain32.70.92
drug ineffective71.50.71
dyspnoea31.40.50
death31.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.